268 related articles for article (PubMed ID: 17962031)
1. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
[TBL] [Abstract][Full Text] [Related]
2. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
3. Expression of NF2 gene product merlin in arachnoid villi and meningiomas.
Sakuda K; Kohda Y; Matsumoto T; Park C; Seto A; Tohma Y; Hasegawa M; Kida S; Nitta H; Yamashima T; Yamashita J
Noshuyo Byori; 1996 Nov; 13(2):145-8. PubMed ID: 8958521
[TBL] [Abstract][Full Text] [Related]
4. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
5. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
[TBL] [Abstract][Full Text] [Related]
6. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
[TBL] [Abstract][Full Text] [Related]
8. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of schwannomin/merlin in human sporadic meningiomas.
Lee JH; Sundaram V; Stein DJ; Kinney SE; Stacey DW; Golubić M
Neurosurgery; 1997 Mar; 40(3):578-87. PubMed ID: 9055299
[TBL] [Abstract][Full Text] [Related]
10. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.
Kalamarides M; Niwa-Kawakita M; Leblois H; Abramowski V; Perricaudet M; Janin A; Thomas G; Gutmann DH; Giovannini M
Genes Dev; 2002 May; 16(9):1060-5. PubMed ID: 12000789
[TBL] [Abstract][Full Text] [Related]
11. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
12. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.
Kimura Y; Saya H; Nakao M
Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929
[TBL] [Abstract][Full Text] [Related]
13. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
14. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
Kirches E; Steffen T; Waldt N; Hebert E; Pachow D; Wilisch-Neumann A; Keilhoff G; Schneider T; Braunsdorf WEK; Warnke JP; Mawrin C
J Neurooncol; 2018 Jun; 138(2):251-259. PubMed ID: 29468444
[TBL] [Abstract][Full Text] [Related]
15. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.
Tanahashi K; Natsume A; Ohka F; Motomura K; Alim A; Tanaka I; Senga T; Harada I; Fukuyama R; Sumiyoshi N; Sekido Y; Wakabayashi T
J Neuropathol Exp Neurol; 2015 Jul; 74(7):704-9. PubMed ID: 26049897
[TBL] [Abstract][Full Text] [Related]
16. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
17. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
18. Loss of merlin-p85 protein complex in NF2-related tumors.
Takeshima H; Nishi T; Yamamoto K; Kino T; Nakamura H; Saya H; Kochi M; Kuratsu JI; Ushio Y
Int J Oncol; 1998 May; 12(5):1073-8. PubMed ID: 9538131
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
